Food and Drug Administration Reauthorization Act of 2017

President Trump quietly signed into law the Food and Drug Administration Reauthorization Act of 2017 which extends the user fee agreements with the pharmaceutical and biotech industries through 2022. Read article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.